George Lundberg, MD Editor in Chief at Cancer Commons

  •  

    How Would an Expert Manage His Own Chronic Myelogenous Leukemia?

    Jerald P. Radich, MD, MA, MSGeorge Lundberg, MD

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks expert oncologist Jerald P. Radich MD, MA, MS, how he would handle his own hypothetical case of chronic myelogenous leukemia (CML). Dr. Radich is the Kurt Enslein Endowed Chair in the Translational Science & Therapeutics Division of the… Read more »

  •   George Lundberg, MD

    Do molecular biomarkers have any role in treating glioblastoma (GBM)? As outlined in this scientific research report from the academic journal Neuro-Oncology Research Advances, a recent study found that 3 biomarkers were correlated with very great outcome differences for people treated with tumor-treating (electrical) fields.

    .

    .

  •   George Lundberg, MD

    The Musella Foundation has announced online availability of the 12th edition of the Brain Tumor Guide for the Newly Diagnosed.

    .

  •   George Lundberg, MD

    As reported by MedPage Today, long-term results from a clinical trial suggest that a combination of the drug pembrolizumab plus chemotherapy is better than chemo alone for small cell lung cancer (SCLC). But unfortunately, most patients who received the combo did not benefit significantly, and biomarkers are very much needed to identify patients whose cancers will respond well.

    .

  •   George Lundberg, MD

    The ASCO Post reports on the U.S. Food And Drug Administration (FDA)’s recent approval of two new treatments for advanced, unresectable squamous cell carcinoma of the esophagus.

    .

  •   George Lundberg, MD

    This article from the International Kidney Cancer Coalition (IKCC) outlines updates on treatment options for renal cell carcinoma as presented at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium.

    .

  •   George Lundberg, MD

    This article from the National Cancer Institute’s Center for Cancer Research outlines new clinical trial results showing that combining the drugs cabozantinib and nivolumab doubled progression-free survival for people with advanced renal cell carcinoma compared to giving cabozantinib alone.

    .

  •   George Lundberg, MD

    This review article in the academic research journal Biomarker Research discusses how combining immunotherapy and targeted therapies provides new hope for people with hepatocellular carcinoma.

    .

  •   George Lundberg, MD

    In this article for Cancer Therapy Advisor, Dr. Shaalan Beg shares updates from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium on treatments for advanced hepatocellular carcinoma.

    .

  •   George Lundberg, MD

    As reported by The ASCO Post, the drug adagrasib has shown some promising results in a clinical trial for people with advanced non-small cell lung cancer (NSCLC) with a KRAS-g12c mutation whose cancer progressed after prior treatment. The U.S. Food and Drug Administration (FDA) allows adagrasib to be given to people whose cancer has a KRAS-g12c mutation through expanded access.

    .